GlassScriptPhysician profile
Jeffrey L Arnold
NPI 1740289800
$4,666.30
in general payments reported to CMS, 2019-2025
42 companies · $1,794 in 2025
The $1,794 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $378 · 2022: $31.29 · 2023: $207 · 2024: $1,037 · 2025: $1,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,037.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $595.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $454.93 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $350.69 | 2024-2025 | Voquezna |
| Abbvie INC. | $245.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $210.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Ironshore Pharmaceuticals INC. | $201.76 | 2019 | |
| Pfizer INC. | $197.53 | 2019-2025 | |
| Shield Therapeutics INC | $186.45 | 2025 | |
| Abbott Laboratories | $186.34 | 2024-2025 | Proclaim, Eterna |
| Lilly USA, LLC | $167.99 | 2019-2025 | Kisunla, Zepbound, Mounjaro |
| Exact Sciences Corporation | $161.68 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $153.14 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $137.89 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $129.67 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.99 | 2019-2025 | Xifaxan |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.